Some investors are hinting that it might be up 900% due to a short squeeze. The company has 34.95M outstanding shares with a float of 24.59M shares and only 65k volume in the last 3 months. A very low float can cause the stock to skyrocket.
Full Answer
How can I get the latest news about Orph?
Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
What will the onph stock price be in the future?
The ONPH ("ONPH" ) future stock price will be 135.600 USD . Will ONPH stock price crash? According to our analysis, this will not happen. Will Oncology Pharma stock price hit 100 USD price in a year?
Who owns Orph a/s?
ORPH stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Renaissance Technologies LLC, Millennium Management LLC, Geode Capital Management LLC, Man Group plc, Schonfeld Strategic Advisors LLC, HAP Trading LLC, and Blueshift Asset Management LLC. How do I buy shares of Orphazyme A/S?
What does sentiment mean on Orphazyme stock?
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen Pre-market Movers: ABVC, BTTX, LAUR, ZSAN, ORPH… Do Options Traders Know Something About Orphazyme (ORPH) Stock We Don't? What's Next For Orphazyme Stock?
Is Orph a good stock to buy?
The consensus among Wall Street equities research analysts is that investors should "hold" Orphazyme A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORPH, but not buy additional shares or sell existing shares.
What is going on with Orphazyme?
In late March 2021, Orphazyme announced its lead asset, arimoclomol, failed to improve disease progression in a phase 2/3 trial for inclusion body myositis, a progressive muscular disorder. Less than two months later, the same asset failed to prove any benefit for ALS patients in a phase 3 trial.
Why is Orphazyme stock up?
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Foa a good stock to buy?
Out of 4 analysts, 1 (25%) are recommending FOA as a Strong Buy, 1 (25%) are recommending FOA as a Buy, 2 (50%) are recommending FOA as a Hold, 0 (0%) are recommending FOA as a Sell, and 0 (0%) are recommending FOA as a Strong Sell. What is FOA's earnings growth forecast for 2022-2024?
Is Orphazyme approved?
In September, Orphazyme announced that FDA accepted, with priority review, the company's new drug application for arimoclomol for NPC treatment.
Is Orph getting delisted?
Orphazyme (NASDAQ:ORPH) is falling after the drugmaker announced today that it would delist its American Depositary Shares. The company said that it had started the delisting process and noted that it will take effect on March 31.
Is Orphazyme a buy?
Signals & Forecast. There are mixed signals in the stock today. The Orphazyme A/S stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal.
Is Orphazyme a good investment?
Orphazyme Stock Price Odds Analysis Given the investment horizon of 90 days the stock has a beta coefficient of 25.1868. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average.
Will Orphazyme get FDA approval?
The FDA has rejected the therapy and asked Orphazyme to provide additional data on the benefits and risks of the heat shock protein amplifier, leading the company to cut costs as the next steps are considered.
Is Finance of America a good stock?
There are currently 3 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Finance Of America Companies stock. View analyst ratings for Finance Of America Companies or view top-rated stocks.
Is Finance of America publicly traded?
We operate in four large and growing markets including Mortgage, Reverse Mortgage, Commercial Real Estate and Fixed Income Investing. On April 1, 2021 we became a publicly traded company. For additional information, please contact us at [email protected].
Is ORPH stock a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orphazyme A/S in the last twelve months. There are currently 1 se...
Who are Orphazyme A/S's key executives?
Orphazyme A/S's management team includes the following people: Mr. Anders Fink Vadsholt M.B.A. , M.Sc., MBA, Chief Financial Officer (Age 52, Pa...
Who are some of Orphazyme A/S's key competitors?
Some companies that are related to Orphazyme A/S include Eliem Therapeutics (ELYM) , Immunic (IMUX) , Checkpoint Therapeutics (CKPT) , Adagene...
When did Orphazyme A/S IPO?
(ORPH) raised $100 million in an IPO on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cow...
What is Orphazyme A/S's stock symbol?
Orphazyme A/S trades on the NASDAQ under the ticker symbol "ORPH."
Who are Orphazyme A/S's major shareholders?
Orphazyme A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%...
Which institutional investors are selling Orphazyme A/S stock?
ORPH stock was sold by a variety of institutional investors in the last quarter, including HAP Trading LLC, Cutler Group LP, and Group One Trading...
Which institutional investors are buying Orphazyme A/S stock?
ORPH stock was acquired by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
How much money does Orphazyme A/S make?
Orphazyme A/S (NASDAQ:ORPH) has a market capitalization of $0.00.
When will Orphazyme get FDA approval?
Orphazyme still hopes to win European approval for arimoclomol in early 2022. The company is also evaluating a potential path to still move forward with seeking FDA approval for the experimental drug.
Who is the Motley Fool?
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
What is ORPH FDA approved?
ORPH is a clinical-stage company working on heat shock protein response for the treatment of rare diseases and arimoclomol is its lead candidate. “Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs).
How much will the Xerox brand make in 2021?
It expects the product to generate revenues between $10-$20 million in 2021 and is also expecting approval in Europe by the end of this year.
Is ORPH making money?
Also, such stocks are very volatile around the release of trial results. Meanwhile, like all clinical-stage companies, ORPH is not making money and posting losses. Losses and cash burn are common for clinical-stage companies as they invest in research and development.
ONPH Target Price
ONPH price target in 14 days: 7.587 USD* upside and 4.783 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Oncology Pharma Inc ( ONPH ) Stock Market info
Recommendations: Buy or sell Oncology Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Oncology Pharma share forecasts, stock quote and buy / sell signals below.